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ORIGINAL ARTICLE
Clear cell chondrosarcoma of bone
KHALID S. AYOUB, ROBERT J. GRIMER, SIMON R. CARTER, DAVID C. MANGHAM,
A.M. DAVIES & ROGER M.TILLMAN
The Royal Orthopaedic Hospital Oncology Service,The Royal Orthopaedic Hospital, Birmingham, UK
Abstract
Purpose. Clear cell chondrosarcoma is a rare variant of chondrosarcoma. Six cases are herein reported.
Subjects. We have treated six patients with clear cell chondrosarcoma in the past 28 years, representing 1.6% of all chond-
rosarcomas seen in this time period.
Results and Discussion. Half the patients had been initially underdiagnosed and inappropriately treated.
Conclusions. Our results and our review of the literature highlight the fact that inadequate initial treatment leads to a high
rate of both local recurrence and metastasis whilst wide initial excision is usually curative.
Key words: clear cell chondrosarcoma, bone tumour, diagnostic imaging, limb-salvage surgical technique.
Introduction
Clear cell chondrosarcoma is a very rare malignant
bone tumour. It was initially described by Unni et al.
in 1976,
1 and was called `Clear-cell Variant of Chon-
drosarcoma’. Up to that time, the tumour had usually
been mistaken for a benign tumour. Because of it’s
rarity this lesion is still being confused with benign or
more malignant bone tumours, both radiologically
and histologically. We have reviewed our experience
in treating clear cell chondrosarcoma at the Royal
Orthopaedic Hospital, Birmingham, with the
advantage of modern methods of diagnostic imaging
and limb-salvage surgical techniques.
Patients and methods
We have undertaken a retrospective review of all
patients with clear cell chondrosarcoma treated by
the Royal Orthopaedic Hospital Oncology Service,
Birmingham, UK. Data has been retrieved from the
departmental computerised database supplemented
by reviews of the case notes, and histological and
radiological studies. Since 1970, six such cases have
been treated, representing 1.6% of the 370 cases of
chondrosarcoma registered at our centre in the last
28 years.
Five patients were male, and one was female. Their
age ranged from 15 to 45 years. The predominant
clinical presentation of the tumour was local pain in
the affected bone of variable duration. Further clinical
details are mentioned in Table 1.
Radiographic features
Initial radiographs were available for review in four of
the six patients (Table 1). All the tumours were situ-
ated in the epiphyseo-metaphyseal area of the long
bones.The most common radiographic features were;
an expansile radiolucent bony lesion, absence of any
periosteal reaction and absence of soft tissue mass
(Fig. 1). Magnetic resonance imaging (MRI) was
obtained for two patients. On T1-weighted images,
the lesion showed relatively homogeneous low to
intermediate signal intensity, and heterogeneous high
signal intensity on T2-weighted images (Fig. 2).
Pathological features
On gross histological examination, the tumours
showed a lobulated mixed soft and solid lesion,
composed of glassy tissue. On microscopic examina-
tion, faint microlobular and osteoblastoma-like
features predominated on low-power examination
(Fig. 3). The constant feature was the presence of
large tumour cells, round-to-oval in shape with distinct
borders, abundant clear cytoplasm and a centrally
located round nucleus (Clear Cell Chondrocytes).
2
Mitotic features were rare, and occasionally these
cells showed eosinophilia. The other predominant
feature was woven bone trabeculae within the micro-
lobules or scattered between sheets of tumour cells.
Multinucleated giant cells were seen in all tumours.
There was variable cartilage matrix production.
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116 K.S.Ayoub et al.Immunohistochemical analysis revealed the tumour
cells were strongly positive to S-100.
Treatment and results
The clinical follow-up ranged from 12 months to 20
years (Table 1). Three patients in our study were
given `inappropriate’ treatment at the referring institu-
tions due to a mistaken provisional diagnosis of a
benign cartilaginous tumour. One of these three
patients had curettage of a tumour in her ilium for
what was thought a chondroblastoma. She developed
local recurrence after 34 months which was treated
by further curettage.Within 4 months, she developed
a rapid-growing local recurrence of the tumour
spreading to the whole hemi-pelvis. Further biopsies
then revealed the diagnosis of clear cell chondrosar-
coma.The patient was offered radical surgical treat-
ment (amputation) which she declined in order to
keep her leg. She underwent a further two-stage
curettage of her tumour and bone cement implanted
in the defect. Five years later, another recurrence
was treated by hindquarter amputation. Eight years
after the amputation, she is still alive and free of
disease.
The second patient was diagnosed initially as a
case of chondromyxoid ® broma of the distal femur
which was treated by curettage. After 63 months he
developed a local recurrence treated by above-knee
amputation following revision of the diagnosis to clear
cell chondrosarcoma. Six months following the
amputation he developed lung metastases and died
shortly after that.
Fig. 1. An anteroposterior view of plain X-ray of the right
proximal femur of a 28-year-old man with clear cell chondrosa-
rcoma. It demonstrates an expansile lytic lesion in the femoral
neck, with thinning of otherwise intact femoral cortex.
Fig. 2. A coronal view of T2-weighted magnetic resonance
imaging (MRI) of pelvis and thighs for the same patient in Fig.
1.It shows the high signal of the tumour in proximal right femur.
Fig. 3. A high power view of a clear cell chondrosarcoma
showing the large tumour chondrocytes, often with clear
cytoplasm, and associated partially mineralized hyaline cartilage
matrix.
Clear cell chondrosarcoma 117The third patient presented to another hospital
with a pathological fracture of the neck of femur
with a provisional clinico-radiological diagnosis of
a benign tumour, possibly chondroblastoma, at the
fracture site. He had a total hip replacement at the
referring hospital. Histological study of the
resected bone con® rmed the diagnosis of clear cell
chondrosarcoma. At 12 months follow-up (the time
of writing this article), there is no evidence of
disease.
The other three patients all had the correct initial
diagnosis of clear cell chondrosarcoma made on
presentation. All had primary wide resection of the
tumour with satisfactory outcomes (Table 1). One of
these three patients had a primary resection and endo-
prosthetic replacement of his proximal femur in 1977.
In 1996 he had revision surgery for aseptic loosening
of the acetabular component of his prosthesis, and
the histological study of the `curettage’ taken from
the acetabulum showed no malignancy. In early
1997, the patient started to show evidence of local
recurrence of the tumour in the ipsilateral ilium.
He underwent en-block excision of the ilium with a
wide margin and reconstructive procedure for
his hemi-pelvis. The histology report of the
resected specimen con® rmed the diagnosis of clear
cell chondrosarcoma, recurring 19 years following
the initial treatment. He remains disease-free two
years later.
In summary, six patients were included in this study.
Three patients had mis-diagnosis of the tumour and
treated with intra-lesional procedures. This resulted
in two local recurrences, and one death due to lung
metastasis.The other three patients in this study had
correct diagnosis and appropriate treatment initially
for the tumour resulting in good outcomes.
Discussion
Clear cell chondrosarcoma was described by Unni et
al. in 1976 when they published a series on 16
patients.
1 It is a very rare malignant bone tumour,
comprising 1.6± 5.4% of all chondrosarcoma,
3± 50.2%
of biopsy-analysed primary bone tumours.
2 Various
suppositions have been made regarding the source of
this tumour. Some considered that the most likely
source of this rare chondrosarcoma variant is the
same group of cells that give rise to chondroblas-
toma.
2 Others suggested that it may represent the
malignant counterpart of chondroblastoma.
6
The age at initial presentation ranges from 13 to
85, although most patients will be in their third to
® fth decades. There is a male predominance of
1.6± 2.6:1.
3,4 Clear cell chondrosarcoma involves the
proximal end of the long bone in 75% of the cases
(60% femur, 15% humerus), 15% around the knee
(distal femur and proximal tibia). In about 10%, the
lesion has been noted in the skull, spine, ribs, pelvis,
ulna or phalanges.
3There have been case reports of
clear cell chondrosarcoma involving more than one
bone.
1 Clinically, the most common presenting
symptom is local pain of long duration. Bjornsson
et al. mentioned in his series of 47 cases, the largest
series published, that 55% of the patients had
symptoms lasting for more than 1 year before their
presentation.
3 Other frequent forms of presenta-
tion were swelling, various disabilities affecting the
adjacent joint and pathological fractures (from 2%
2
to 37%
1). Some of the others were asymptomatic
and the lesion discovered as an incidental ® nding
on plain x-ray.
Radiographically, when the tumour affects the long
bone, the lesion is almost always located in the
Table 2. Outcome of treatments by comparison
Bjornosson
3
(n=47) Present
4 (n=8) Laporte
5 (n=13) Our study (n=6) (Total) Average
d
I. No of patients
with adequate
treatment
a
22 6 9 3 (40)
Local recurrence 3(14%) 0 0 1(33%) 10%
Metastases 2(9%) 0 0 0 5%
Deaths 1(4%) 0 0 0 2.5%
II. No of patients
with inadequate
treatment
b
22 2 3 3 (30)
Local recurrence 15(68%) 0 2(66%) 2(66%) 63%
Metastases 6(27%) 0 1(33%) 1(33%) 27%
Deaths 7(32%) 0 1(33%) 1(33%) 30%
Total no. of
patients
c
44 8 12 6
a\Adequate treatment means complete surgical removal of tumour as primary treatment (i.e. en-bloc resection,
amputation).
bInadequate treatment means all treatment methods other than those mentioned in (
a) above.
cNo. of patients with only adequate follow-up information considered in this table.
dThe `Average’ is obtained by dividing the sum of patients who had the speci® c complication (e.g. local recurrence)
reported in those series by the total number of patients in either of the main groups (i.e. adequate or inadequate treatment
group), multiplied by 100.
118 K.S.Ayoub et al.epihyseal area with or without extension to the meta-
physis. Very few cases are reported with tumour
extending to or located entirely in the diaphysis.
3,7
The most common radiographic features on plain
X-ray, as described in this study and the previous
literature,
1± 4,7 are; radiolucency (83%), expansion of
the bone (75%), densi® cation/calci® cation (45%), a
border between tumour and host bone with or without
sclerotic rim (49%), cortical involvement, often in
the form of thinning (71%), the cortex was intact in
the majority of cases and periosteal reaction (3%).
Soft tissue masses are very rare (less than 10%). On
computed tomography (CT), the appearances are
similar to those seen on plain X-ray but CT is more
sensitive at detecting calci® cation and cortical involve-
ment.
8,9The magnetic resonance imaging (MRI) of
this tumour tends to show a well demarcated
geographic lesion with intermediate signal intensity
on T1-weighted images, and a higher signal intensity
on T2-weighted images.
10± 12 All these features are
non speci® c. Differential diagnoses frequently
reported include chondroblastoma, giant cell tumour,
chondroma, chondromyxoid ® broma and cysts. If the
tumour showed any malignant features, the differential
diagnoses include osteosarcoma, malignant ® brous
histiocytoma and ® brosarcoma.
The slow-growing nature of clear cell chondrosar-
coma and the apparently benign radiographic and
histological appearances in the majority of cases often
results in difficulty in diagnosing the tumour at an
early stage, with subsequent provision of conserva-
tive treatment.Various treatment modalities were used
with fairly consistent outcomes throughout many
published series. Intra-lesional surgical removal of
the tumour (e.g. curettage, incomplete excision) yields
an unacceptably high local recurrence of
approximately 83
1 to 86%,
3 and death rate from 29
3
to 50%.
1 In contrast, complete surgical removal of
the tumour with a wide margin of disease-free tissue
(e.g.en-bloc resection, primary amputation) has given
a lower local recurrence rate of less than 15%,
3 and
much lower death rate.
1,3,5 Radiotherapy was
employed as an initial treatment with some claimed
local control but poor outcome.
1,3 Amputation was
used in a few patients, usually when the initial
diagnosis was incorrect and hence amputation was a
salvage procedure.
1,3 From our experience in this
study and from the larger published studies,
1,3± 5 we
con® rm that inadequate treatment (e.g. curettage,
incomplete excision, radiotherapy and chemotherapy
as a primary treatment) certainly yields a poorer result
compared with the adequate treatment (en-block exci-
sion of the tumour as a primary treatment) summarised
in Table 2. Only patients with adequate follow-up
information are considered in this table for comparison.
Conclusion
Clear cell chondrosarcoma is a low-grade and slow-
growing tumour. Cure can be achieved by wide local
excision in the majority of cases. Awareness of the
condition and the diagnostic pitfalls will help improve
both detection and survival.
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